BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12970171)

  • 1. Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.
    Hurlin PJ; Zhou ZQ; Toyo-oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    EMBO J; 2003 Sep; 22(18):4584-96. PubMed ID: 12970171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
    Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
    Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
    Popov N; Wahlström T; Hurlin PJ; Henriksson M
    Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mnt takes control as key regulator of the myc/max/mxd network.
    Wahlström T; Henriksson M
    Adv Cancer Res; 2007; 97():61-80. PubMed ID: 17419941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
    Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
    J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.
    Dezfouli S; Bakke A; Huang J; Wynshaw-Boris A; Hurlin PJ
    Mol Cell Biol; 2006 Mar; 26(6):2080-92. PubMed ID: 16507988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
    Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
    Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of Myc and Mnt.
    Hooker CW; Hurlin PJ
    J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.
    Greider C; Chattopadhyay A; Parkhurst C; Yang E
    Oncogene; 2002 Nov; 21(51):7765-75. PubMed ID: 12420213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of mnt-myc antagonism revealed by mnt gene deletion.
    Hurlin PJ; Zhou ZQ; Toyo-Oka K; Ota S; Walker WL; Hirotsune S; Wynshaw-Boris A
    Cell Cycle; 2004 Feb; 3(2):97-9. PubMed ID: 14712062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation.
    Nilsson JA; Maclean KH; Keller UB; Pendeville H; Baudino TA; Cleveland JL
    Mol Cell Biol; 2004 Feb; 24(4):1560-9. PubMed ID: 14749372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.
    Link JM; Ota S; Zhou ZQ; Daniel CJ; Sears RC; Hurlin PJ
    Proc Natl Acad Sci U S A; 2012 Nov; 109(48):19685-90. PubMed ID: 23150551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p27kip1-independent cell cycle regulation by MYC.
    Berns K; Martins C; Dannenberg JH; Berns A; te Riele H; Bernards R
    Oncogene; 2000 Oct; 19(42):4822-7. PubMed ID: 11039898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity.
    Berns K; Hijmans EM; Bernards R
    Oncogene; 1997 Sep; 15(11):1347-56. PubMed ID: 9315103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for a cancer-specific switch at the CDK4 promoter with loss of control by both USF and c-Myc.
    Pawar SA; Szentirmay MN; Hermeking H; Sawadogo M
    Oncogene; 2004 Aug; 23(36):6125-35. PubMed ID: 15208653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene.
    Rao RN; Stamm NB; Otto K; Kovacevic S; Watkins SA; Rutherford P; Lemke S; Cocke K; Beckmann RP; Houck K; Johnson D; Skidmore BJ
    Oncogene; 1999 Nov; 18(46):6343-56. PubMed ID: 10597234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinases regulate the antiproliferative function of Smads.
    Matsuura I; Denissova NG; Wang G; He D; Long J; Liu F
    Nature; 2004 Jul; 430(6996):226-31. PubMed ID: 15241418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.